DETAILED ACTION
Notice of Pre-AIA or AIA Status
1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Status
2. The claims filed Aug 29, 2025 have been entered. Claims 1-5 are under consideration in this Office Action.
Information Disclosure Statement
3. The information disclosure statement (IDS) submitted on Aug, 29, 2025 was filed. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
4. The specification lacks complete deposit information for the deposit of the strain of S. salivarius strain KCCN13161P. Because it is not clear that cell lines possessing the properties of strain of S. salivarius strain KCCN13161P are known and publicly available or can be reproducibly isolated from nature without undue experimentation and because the claims require the use of strain of S. salivarius strain KCCN13161P, a suitable deposit for patent purposes is required. Without a publicly available deposit of the above cell line, one of ordinary skill in the art could not be assured of the ability to practice the invention as claimed. Exact replication of the cell line is an unpredictable event.
If a deposit has been made under the provisions of the Budapest Treaty, filing of an affidavit or declaration by applicant or assignees or a statement by an attorney of record who has authority and control over the conditions of deposit over his or her signature and registration number stating that the deposit has been accepted by an International Depository Authority under the provisions of the Budapest Treaty, that all restrictions upon public access to the deposit will be irrevocably removed upon the grant of a patent on this application and that the deposit will be replaced if viable samples cannot be dispensed by the depository is required. This requirement is necessary when deposits are made under the provisions of the Budapest Treaty as the Treaty leaves this specific matter to the discretion of each State. Amendment of the specification to recite the date of deposit and the complete name and full street address of the depository is required.
If the deposit has not been made under the provisions of the Budapest Treaty, then in order to certify that the deposits comply with the criteria set forth in 37 CFR §1.801-1.809, assurances regarding availability and permanency of deposits are required. Such assurance may be in the form of an affidavit or declaration by applicants or assignees or in the form of a statement by an attorney of record who has the authority and control over the conditions of deposit over his or her signature and registration number averring:
(a) during the pendency of this application, access to the deposits will be afforded to the Commissioner upon request;
(b) all restrictions upon the availability to the public of the deposited biological material will be irrevocably removed upon the granting of a patent on this application;
(c) the deposits will be maintained in a public depository for a period of at least thirty years from the date of deposit or for the enforceable life of the patent of or for a period of five years after the date of the most recent request for the furnishing of a sample of the deposited biological material, whichever is longest; and
(d) the deposits will be replaced if they should become nonviable or non-replicable.
In addition, a deposit of biological material that is capable of self-replication either directly or indirectly must be viable at the time of deposit and during the term of deposit. Viability may be tested by the depository. The test must conclude only that the deposited material is capable of reproduction. A viability statement for each deposit of a biological material not made under the Budapest Treaty must be filed in the application and must contain:
1) The name and address of the depository;
2) The name and address of the depositor;
3) The date of deposit;
4) The identity of the deposit and the accession number given by the depository;
5) The date of the viability test;
6) The procedures used to obtain a sample if the test is not done by the depository; and
7) A statement that the deposit is capable of reproduction.
As a possible means for completing the record, applicant may submit a copy of the contract with the depository for deposit and maintenance of each deposit.
If the deposit was made after the effective filing date of the application for patent in the United States, a verified statement is required from a person in a position to corroborate that the hybridoma cell line described in the specification as filed is the same as that deposited in the depository. Corroboration may take the form of a showing of a chain of custody from applicant to the depository coupled with corroboration that the deposit is identical to the biological material described in the specification and in the applicant's possession at the time the application was filed.
Applicant's attention is directed to In re Lundack, 773 F.2d. 1216, 227 USPQ 90 (CAFC 1985) and 37 CFR §1.801-1.809 for further information concerning deposit practice.
Claim Rejections - 35 USC § 112
5. Claims 1-5 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for reducing P. gingivalis in a human subject, comprising administering to a human subject in need thereof a composition comprising Streptococcus salivarius strain KCCM13161P (S. salivarius G7, KCCM13161P), wherein the reduction is compared human subject which was not administered Streptococcus salivarius strain KCCM13161P (S. salivarius G7, KCCM13161P);
does not reasonably provide enablement for a method of preventing or alleviating an oral disease by inhibiting oral pathogens, comprising administering to a human subject in need thereof a composition comprising at least one selected from the group consisting of: Streptococcus salivarius strain KCCM13161P (S. salivarius G7, KCCM13161P), a lysate thereof, a concentrate thereof, a dried product thereof, a culture thereof, an extract thereof, a thermally treated culture dried product thereof, and a fraction thereof. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make/use the invention commensurate in scope with these claims. This is a scope of enablement rejection.
Factors to be considered in determining whether a disclosure meets the enablement requirement of 35 USC 112, first paragraph, have been described by the court in In re Wands, 8 USPQ2d 1400 (CAFC 1988),page 1404.
Enablement is considered in view of the Wands factors (MPEP 2164.01 (A)). These include: nature of the invention, breadth of the claims, guidance of the specification, the existence of working examples, state of the art, predictability of the art and the amount of experimentation necessary. In re Fisher, 427 F.2d 833,839, 166 USPQ 18, 24 (CCPA 1970) states, "The amount of guidance or direction needed to enable the invention is inversely related to the amount of knowledge in the state of the art as well as the predictability in the art." "The "amount of guidance or direction" refers to that information in the application, as originally filed, that teaches exactly how to make or use the invention. The more that is known in the prior art about the nature of the invention, how to make, and how to use the invention, and the more predictablethe art is, the less information needs to be explicitly stated in the specification. In contrast, if little is known in the prior art about the nature of the invention and the art is unpredictable, the specification would need more detail as to how to make and use the invention in order to be enabling" (MPEP 2164.03). The MPEP further states that physiological activity can be considered inherently unpredictable. Thus, Applicant assumes a certain burden in establishing that inventions involving physiological activity are enabled. All of the Wands factors have been considered with regard to the instant claims, with the most relevant factors discussed below.
Nature of the invention: The nature of the invention is a method for preventing or alleviating an oral disease by inhibiting oral pathogens, comprising administering to a human subject in need thereof a composition comprising at least one selected from the group consisting of: Streptococcus salivarius strain KCCM13161P (S. salivarius G7, KCCM13161P), a lysate thereof, a concentrate thereof, a dried product thereof, a culture thereof, an extract thereof, a thermally treated culture dried product thereof, and a fraction thereof; wherein the relative level of skill of those in the art is deemed to be high.
Breadth of the claims: The claims are broadly drawn to an a method of preventing or alleviating an oral disease by inhibiting oral pathogens, comprising administering to a human subject in need thereof a composition comprising at least one selected from the group consisting of: Streptococcus salivarius strain KCCM13161P (S. salivarius G7, KCCM13161P), a lysate thereof, a concentrate thereof, a dried product thereof, a culture thereof, an extract thereof, a thermally treated culture dried product thereof, and a fraction thereof. Thus, the claim encompasses preventing or alleviating each and every types of oral disease with the exact same administration.
Guidance of the specification/The existence of working examples: The specification teaches the FIG. 17 , the number of bacteria of S. salivarius G7 (Accession No. KCCM13161P) in the biofilm increased with an increasing amount of treatment thereof, but the number of bacteria of S. mutans, a causative bacterium of dental caries, significantly decreased with an increasing amount of treatment of S. salivarius G7 (Accession No. KCCM13161P) of the present disclosure. However, no subjects of any kind were administered S. salivarius G7. The examples within the instant specification. There is no teaching of administering a lysate, concentrate, dried product, culture, extract, thermally treated culture, culture dried product or fraction of S. salivarius G7, to any subject. There is no teaching of alleviating any oral disease by reducing the severity, pain, and symptoms of conditions affecting the mouth, teeth, and gums in any human or other subject. There is no prevention of the numerous oral diseases.
There is merely a general suggestion of that do not apply directly to the instant invention. There are no working examples of the claimed S. salivarius G7. Thus, the scope of the scope of the claims is extremely broad compared to the guidance and exemplification provided in the specification. The scope of the claims must bear a reasonable correlation with the scope of enablement. See In re Fisher, 166 USPQ 19 24 (CCPA 1970).
State of the art: The state of the prior art is such that it is well established in the art that there is no single administration which can prevent all or many oral diseases. Oral diseases include dental caries, chronic gingivitis and periodontitis, oral precancer and cancer, noma (cancrum oris) oral manifestations of HIV/AIDS, developmental disorders involving teeth and craniofacial structures such as cleft lip and palate, fluorosis of teeth. See Bratthall D, Petersen PE, Stjernswärd JR, et al. Oral and Craniofacial Diseases and Disorders. In: Jamison DT, Breman JG, Measham AR, et al., editors. Disease Control Priorities in Developing Countries. 2nd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2006. Chapter 38.
There is no prevention of anodontia, taurodontism, talon cusps, radiculomegaly, aggressive juvenile periodontitis, pemphigus vulgaris, amelogenesis and dentinogenesis imperfecta. There is no prevention of oral actinomycosis, oral candidiasis, oral herpes or hand, foot and mouth disease by the administration of a lysate, concentrate, dried product, culture, extract, thermally treated culture, culture dried product or fraction of S. salivarius G7. One can does not prevent oral cancer by the instantly claimed administration. Thus, the state of the art recognized that it would be highly unpredictable with regard to the method of preventing or alleviating an oral disease by inhibiting oral pathogens, comprising administering to a human subject in need thereof a composition comprising at least one selected from the group consisting of: Streptococcus salivarius strain KCCM13161P (S. salivarius G7, KCCM13161P), a lysate thereof, a concentrate thereof, a dried product thereof, a culture thereof, an extract thereof, a thermally treated culture dried product thereof, and a fraction thereof.
Relative Skill of Those in the Art: One of ordinary skill in the art could not predictably extrapolate the teachings in the specification, limited to a method of preventing or alleviating any type of oral disease by inhibiting oral pathogens, comprising administering to a human subject in need thereof a composition comprising at least one selected from the group consisting of: Streptococcus salivarius strain KCCM13161P (S. salivarius G7, KCCM13161P), a lysate thereof, a concentrate thereof, a dried product thereof, a culture thereof, an extract thereof, a thermally treated culture dried product thereof, and a fraction thereof, as broadly as claimed. In view of the lack of support in the art and specification for an effective and protective composition, it would require undue experimentation on the part of the skilled artisan to make and use the claimed method of prevention and alleviation; therefore the full scope of the claims is not enabled.
The scope of the scope of the claims is extremely broad compared to the guidance and exemplification provided in the specification and the specification fails to teach such. The specification fails to show a single challenge experiment. Therefore the scope of enablement does not embrace a method as instantly claimed. Moreover, there is no teaching as to the general guidelines or the production of a protective immune response to prevent or alleviate the oral disease or its related symptoms.
The specification does not enable the genus because where the results are unpredictable, the disclosure of a single species usually does not provide an adequate basis to support generic claims. In re Soll, 97 F.2d 623, 624, 38 USPQ 189, 191 (CCPA 1938). In cases involving unpredictable factors, such as most chemical reactions and physiological activity, more may be required. In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970) (contrasting mechanical and electrical elements with chemical reactions and physiological activity). See also In re Wright, 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993); In re Vaeck, 947 F.2d 488, 496, 20 USPQ2d 1438, 1445 (Fed. Cir. 1991). This is because it is not obvious from the disclosure of one particular species, what other species will work. See MPEP 2164.03. One of skill in the art would neither expect nor predict the appropriate functioning of the vaccine as broadly as is claimed. Without such guidance, the changes which can be made in polypeptides structure and still function as a vaccine is unpredictable and the experimentation left to those skilled in the art is unnecessarily and improperly extensive and undue. See Amgen, Inc. v. Chugai Pharmaceutical Co. Ltd., 927 F, 2d 1200, 18 USPQ 1016 (Fed. Cir. 1991) at 18 USPQ 1026 1027 and Ex parte Forman, 230 USPQ 546 (BPAI 1986).
In view of the lack of the predictability of the art to which the invention pertains as evidenced by the state of the art, the lack of guidance and direction provided by applicant, and the absence of working examples, undue experimentation would be required to practice the claimed method with a reasonable expectation of success, absent a specific and detailed description in applicant’s specification of how to effectively prevent or alleviate any oral disease by inhibiting oral pathogens, comprising administering to a human subject Streptococcus salivarius strain KCCM13161P (S. salivarius G7, KCCM13161P); commensurate in scope with the claimed invention.
Applicants’ have provided no guidance to enable one of ordinary skill in the art as to how determine, without undue experimentation, the prevention and/or alleviation of the numerous oral diseases by administering S. salivarius G7, KCCM13161P; therefore, one of skill in the art would have to locate de novo steps required for a method of preventing or alleviating an oral disease by inhibiting oral pathogens
Given the lack of guidance contained in the specification and the unpredictability for preventing or alleviating an oral disease by inhibiting oral pathogens, one of skill in the art could not make or use the broadly claimed invention without undue experimentation. The specification fails to provide an enabling disclosure for a method for preventing or alleviating an oral disease by inhibiting oral pathogens, simply comprising a single administration for each and every different oral disease. In view of the lack of guidance contained in the specification and the unpredictability for preventing or alleviating an oral disease by inhibiting oral pathogens, one skilled in the art could not make or use the broadly claimed invention without undue experimentation.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
6. Claims 1-5 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
The claims are drawn to a method for preventing or alleviating an oral disease by inhibiting oral pathogens, comprising administering to a human subject in need thereof a composition comprising at least one selected from the group consisting of: Streptococcus salivarius strain KCCM13161P (S. salivarius G7, KCCM13161P), a lysate thereof, a concentrate thereof, a dried product thereof, a culture thereof, an extract thereof, a thermally treated culture dried product thereof, and a fraction thereof. It is unclear the if the lysate, concentrate, dried product, a culture, an extract, a thermally treated culture dried product, and a fraction are claiming any kind of lysate concentrate without any required components or the KCCM13161P; or if the lysate, concentrate, etc must include the S. salivarius KCCM13161P strain or the lysate etc must include the S. salivarius G7 strain. The metes and bounds of what is being administered is unclear. Therefore, the claim language requires clarification in order to overcome this rejection.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
7. Claims 1-5 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Stowik [Contribution of Probiotics Streptococcus salivarius Strains K12 and M18 to Oral Health in Humans: A Review. (Turner A. Stowik University of Connecticut. DEPARTMENT OF MOLECULAR AND CELL BIOLOGY THE UNIVERSITY OF CONNECTICUT HONORS PROGRAM MAY 2016)].
The claims are drawn to a method for preventing or alleviating an oral disease by inhibiting oral pathogens, comprising administering to a human subject in need thereof a composition comprising at least one selected from the group consisting of: a lysate thereof, a concentrate thereof, a dried product thereof, a culture thereof, an extract thereof, a thermally treated culture dried product thereof, and a fraction thereof.
It is noted that the broadest reasonable interpretation of lysate thereof, fraction thereof and other by-products thereof as instantly claimed are not limited to S. salivarius G7, or the deposited KCCM13161P strain and fairly encompass any strain of S. salivarius.
Stowik describe two bacterial strains with clinically-significant probiotic applications in curtailing the pathogenic bacterial growth involved in these conditions are Streptococcus salivarius strain K12 and Streptococcus salivarius strain M18. To summarize the most up-to-date in vitro, in vivo, and clinical research findings, administration of these S. salivarius strains typically in the form of probiotic lozenges results in colonization, reduction in inflammatory measures, and marked alterations to physical structure & gene expression of the oral epithelial cells of the pharynx, tongue, and buccal membrane [abstract]. While K12 and M18’s reduction of pharyngitis and halitosis has been largely attributed to bacteriocin production, the probiotic strains utilize different modes of action to reduce other oral pathologies. The prevention of dental caries, gingivitis and oral candidiasis appears to be ultimately influenced by K12 and M18’s production of dextranase & urease, reduction of inflammatory cytokines, and direct physical attachment to pathogens, respectively. In addition to conferring several oral health benefits, these S. salivarius strains have been proven extremely safe for human consumption in clinical trials and have the potential for universal application as an alternative treatment to antibiotics in the aforesaid oral pathologies [abstract].
Due to K12’s bacteriocin profile that effectively inhibited strep-throat-causing bacterial species in preliminary studies, BLIS K12[Symbol font/0xD4] was commercially developed and thus became the first S. salivarius K12 oral probiotic to specifically target oral health [Introduction]. When K12 and M18 are first introduced into the oral cavity typically in the form of a probiotic lozenge, they must colonize specific oral regions and be tolerated by the human host. Once the bacteria establish themselves, they can then confer their individually distinct oral health benefits to the human host [Introduction]. Treatment with S. salivarius M18 effectively reduces a patient’s risk of developing dental caries through a molecular mechanism that increases oral pH and reduces plaque formation. In one study, the risk of a patient developing dental caries is assessed through Cariogram, a software program that identifies the relative risk of developing caries based on nine pathological and protective factors, coupled with the expertise of the dentist.16 When children who are at “high risk” for developing caries are treated with Carioblis[Symbol font/0xE2], an oral probiotic containing S. salivarius M18, they are less likely to develop dental caries based on the Cariogram outcome following a 90-day regimen [(2) Dental Caries].
Treatment with S. salivarius M18 effectively reduces a patient’s risk of developing dental caries through a molecular mechanism that increases oral pH and reduces plaque formation. In one study, the risk of a patient developing dental caries is assessed through Cariogram, a software program that identifies the relative risk of developing caries based on nine pathological and protective factors, coupled with the expertise of the dentist.16 When children who are at “high risk” for developing caries are treated with Carioblis[Symbol font/0xE2], an oral probiotic containing S. salivarius M18, they are less likely to develop dental caries based on the Cariogram outcome following a 90-day regimen [(3) Gingivitis & Periodontitis]. When lozenges containing S. salivarius K12 are consumed for a week by human subjects with high VSC levels, their VSC levels were significantly reduced in 85% of test subjects, indicating a reduction in this important marker of halitosis [(4) Halitosis]. The reduction of oral candidiasis by S. salivarius K12 can be attributed not to a direct fungicidal effect, but to the bacterium’s ability to directly bind to hyphae of C. albicans. The probiotic microbe surrounds and attaches to C. albicans during fungal germ tube formation and mycelial expansion, which reduces the pathogenic yeast’s ability to adhere to substrates. K12 preferentially binds to the fungal mycelia but not to individual yeast cells themselves [(5) Oral Candidiasis].
Stowik teach a method for preventing or alleviating an oral disease by inhibiting oral pathogens, comprising administering to a human subject in need thereof a composition comprising at least one selected from the group consisting of: Streptococcus salivarius strain KCCM13161P (S. salivarius G7, KCCM13161P), a lysate thereof, a concentrate thereof, a dried product thereof, a culture thereof, an extract thereof, a thermally treated culture dried product thereof, and a fraction thereof; as a lozenges /candy and tablets and or capsules. Therefore, the instant claims are rejected.
Pertinent Art
8. The prior art made of record and not relied upon is considered pertinent to applicant’s disclosure.
Carioblis® are slow oral dissolution tablets.
BLIS K12[Symbol font/0xD4] delivers 2.5 billion CFU per lozenge
Power et al., (Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis 27, 1261–1263 (2008).
9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JA-NA A HINES whose telephone number is (571)272-0859. The examiner can normally be reached Monday thru Thursday.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor Peter Paras, can be reached on 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/JANA A HINES/Primary Examiner, Art Unit 1645